This hearing gave the EAEPC the occasion to contest again the EU Commission approach regarding Glaxo’s anti-competitive pricing practices in Spain.

Indeed, while the EU Commission still denies EAEPC’s demand to investigate on the practices implemented by Glaxo after the withdrawal of their initial dual pricing system, the EAEPC claims that anti-competitive practices not only persist but also spread among other pharmaceutical companies.

EAEPC therefore asked the EU judges to oblige the European Commission to re-open the case and carry further investigations on Glaxo’s practises and their detrimental impact on the parallel trade of medicines.

For further information : Glaxo pricing practices spread like ‘virus in Spain amid EU antitrust ‘limbo’, court hears by Mari Eccles in MLex 4th April 2017.